are cancer therapeutics composed of a human antibody linked to a toxin that will enter and kill the cancer cells. The antibody portion of the drug binds specifically to a target on a cancer cell, allowing the drug to be internalized. Thus, ADCs act as a “guided missile” to selectively target and kill cancer cells.
Despite recent progress in ADC development – including improvements in conjugation methods, linkers and payloads – the need for novel ADC targets remains. New targets are critical for cancers not yet treatable with existing therapies and for cancers that have resistance mechanisms to existing drugs. Novel target discovery enables ADC innovation in the treatment of various cancers with unmet need and gives doctors and patients new therapeutic options.
We are utilizing our proprietary target discovery technologies to develop first-in-class ADC therapeutics. Our in vivo SPARTA technology augments traditional discovery methods and leverages biology to develop targets specific to cancer cells that are accessible in the body and internalize into the cancer cells upon binding.
MBrace technology also provides accessibility to a wide range of potential new candidate targets. This novel approach has the potential to not only discover new drug candidates, but also to manufacture drugs for a class of new candidates that have, to date, been inaccessible due to technical issues.